Compare DOLE & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | KRSA |
|---|---|---|
| Founded | 1851 | 2024 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | DOLE | KRSA |
|---|---|---|
| Price | $13.76 | $32.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $17.55 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.2M | 159.4K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $9,172,907,000.00 | $2,074,000.00 |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $1.92 | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ 8.23 | 3.70 |
| 52 Week Low | $12.59 | $29.03 |
| 52 Week High | $16.51 | $37.27 |
| Indicator | DOLE | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.91 | 52.17 |
| Support Level | $12.83 | $29.67 |
| Resistance Level | $13.92 | $34.51 |
| Average True Range (ATR) | 0.46 | 1.95 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 55.77 | 63.32 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.